Device Sutures

Vicryl

Payments companies reported to CMS as associated with Vicryl. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$283Kassociated payments (2023-2025)

356clinicians with associated payments

5companies reporting

By year

2023 $54K

2024 $160K

2025 $69K

Payments reported as associated with Vicryl, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Adult Reconstructive Orthopaedic Surgery $93K

Orthopaedic Surgery of The Spine $54K

Colon & Rectal Surgery $42K

Plastic Surgery $34K

Thoracic Surgery (Cardiothoracic Vascular Surgery) $12K

Ophthalmology $5,312

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Vicryl

These are the largest totals companies reported as associated with Vicryl. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Antonia Chen	Dallas, TX	Adult Reconstructive Orthopaedic Surgery	$86,638.07
Eric Klineberg	Sacramento, CA	Orthopaedic Surgery of The Spine	$53,942.32
Najjia Mahmoud	Philadelphia, PA	Colon & Rectal Surgery	$32,943.75
Christopher Reid	San Diego, CA	Plastic Surgery	$26,949.04
Diego Marines Copado	Houston, TX	Colon & Rectal Surgery	$9,000.00
Linda Suleiman	Chicago, IL	Adult Reconstructive Orthopaedic Surgery	$4,200.00
Isaac George	New York, NY	Thoracic Surgery (Cardiothoracic Vascular Surgery)	$4,166.25
Adam Kopelan	Millburn, NJ		$3,678.75
Chun Choi	Cherry Hill, NJ	Thoracic Surgery (Cardiothoracic Vascular Surgery)	$3,025.00
Donald Buck	Saint Louis, MO	Plastic Surgery	$2,800.00

Prescribed Vicryl?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.